Dec. 30 at 4:01 AM
$BWAY We’re excited to see Radial announce earlier this month
$50M in funding led by General Catalyst to expand access to advanced brain medicine, a step that validates the growing impact of evidence-based neurostimulation therapies.
Why this matters:
Nearly 1 in 5 U.S. adults lives with a mental health condition, yet standard treatments only achieve ~10% remission.
Breakthrough interventions like TMS (including BrainsWay’s Deep TMS™) and other brain-directed therapies show remission rates of 50–60%, with some studies up to 78%, often in days to weeks.
Expanding access, infrastructure, and reimbursement for these treatments means more patients can benefit from rapid, effective relief.
At BrainsWay, we continue to innovate and lead in noninvasive brain stimulation, working alongside partners like Radial to make modern brain medicine routine, reliable, and accessible for millions of people who need it most.
https://endpoints.news/radial-raises-50m-to-treat-mental-health-in-non-traditional-ways/
